Zymeworks Completes Acquisition of Theravance Biopharma

Source excerpt

EX-99.1 5 d270232dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Zymeworks Completes Acquisition of Theravance Biopharma • Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET) Vancouver, British Columbia (September 23, 2026) – Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows. Zymeworks will host a conference call with investors and the general public at 8:30 am ET on Monday, September 28, to discuss the final transaction details of the acquisition. Dial-in details and webcast link are available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations . A replay of the webcast will be available within 24 hours following the conclusion of the call and will remain archived for a limited period. About Zymeworks Inc. Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregat

SEC 8-K